SPONSOR
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Total Trials
4
Recruiting
4
Phases
Phase 1, Phase 3, Phase 2
NCT06736327 Phase 1
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Advanced Solid Tumors
NCT06711900 Phase 3
Recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT07019675 Phase 2
Recruiting
A Study of SKB518 in Patients With Lung Cancer
Lung Carcinoma
NCT06725381 Phase 1
Recruiting
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Solid Malignancies